Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus

Neurology

Volumn 78, Issue 11, 2012, Pages 840-

  Santulli, Gaetano ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN ISCHEMIA; DIABETES MELLITUS; DIABETIC PATIENT; FIBRINOLYTIC THERAPY; HUMAN; LETTER; MEDICAL HISTORY; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; FEMALE; MALE; METHODOLOGY; NOTE; PATHOPHYSIOLOGY;

BRAIN ISCHEMIA; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84859935745     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31824de51b     Document Type: Editorial

References (5)

1. Mishra NK, Ahmed N, Davalos A, et al. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology 2011;77:1866 -1872.
2. Demaerschalk BM. Challenging the validity of imposing contraindications to thrombolysis for acute ischemic stroke. Neurology 2011;77:1862-1863.
3. Tong D. Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine. Neurology 2011;76:1780-1781.
4. Rubiera M, Ribo M, Santamarina E, et al. Is it time to reassess the SITS-MOST criteria for thrombolysis? A comparison of patients with and without SITS-MOST exclusion criteria. Stroke 2009;40:2568-2571.
5. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-2037.